Compound tracker

CYB003 / deuterated psilocin analog.

A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.

1 trial rows 0 update rows Latest checked: May 15, 2026 All trials

Claim boundary

Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Check each source note before turning a row into a claim.

Backlinks

This page links out to registry/source records, the global trial tracker, the updates feed, and matching wiki dossiers when available.

Trial rows

Phase 3

Phases tracked

Recruiting

Statuses seen

Trial rows

NCT06793397 Phase 3 Recruiting updated May 15, 2026

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (EMBRACE)

Condition: Major Depressive Disorder
Sponsor / institution: Cybin IRL Limited; Worldwide Clinical Trials
Start date: Dec 10, 2025

Tracker note / source boundary

Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry watch only; CYB003 remains investigational; recruiting/Phase 3 status does not establish efficacy, safety, approval, label, reimbursement, or access. Registry: Phase 3 EMBRACE multicenter randomized quadruple-masked trial, estimated n=330, CYB003 8mg or 16mg in two dosing sessions about three weeks apart vs placebo, adjunctive to antidepressants with psychological support; primary outcome MADRS through Day 84/End of Trial; estimated completion 2027-05-08.

Related updates

No source-update rows are currently linked to this compound.

Conditions touched

Major Depressive Disorder